期刊文献+

氨磷汀在淋巴瘤患者化疗中的保护作用 被引量:3

下载PDF
导出
摘要 目的评价细胞保护剂氨磷汀在淋巴瘤患者化疗中对机体的保护作用。方法采用随机、开放、对照的原则,选择25例淋巴瘤患者,化疗60例次,分两组,观察组化疗前应用氨磷汀,对照组不用,比较两组间化疗后血细胞及肝肾功能的变化情况。结果观察组与对照组比较,化疗后血液毒性和肝损明显减轻,统计学处理有显著性差异。结论氨磷汀对淋巴瘤化疗患者的机体功能有一定的保护作用,尤其对骨髓造血细胞有较好的保护作用。
出处 《江西医药》 CAS 2008年第6期565-567,共3页 Jiangxi Medical Journal
  • 相关文献

参考文献6

  • 1Fisher R I,Gaynor E R,Dahlberg S,et al.Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lemphoma. N Engl J Med, 1993,328,14:1002
  • 2黄关宏,高健,许昌韶.细胞保护剂氨磷汀[J].中国血液流变学杂志,2003,13(2):189-193. 被引量:4
  • 3Hartmann JT,Von vangerow A,Fels LM, et al. A randnomized trial of amifostine in patients with highdose IVC chemotherapy plus autologous blood stem cell transplantation.Br J Cancer ,2001,84(3):313
  • 4Calabro-Jones P,Aguilera J,Ward J,et al.Up take ofamifostine derivatives by cells in culture: Identification of thetransported form of the drug.Cancer Res,1988, 48(13):3634
  • 5Ghielmini M, Van der Bosch S, Bosshard M, et al. PhaseI-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. Cancer Chemother Pharmacol,2001,47(6) :532
  • 6Balzarotti M,Crisanti S,Granzow K,et al.Exvivo manipulation of hematopoietic stem cells for transplantation the potential role of amifostion.Semi Oncol,1999,26(2 Supp17):66

二级参考文献28

  • 1[11]Peter G Rose. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma[J]. Semin-Oncol, 1996,23(4 suppl 8) :83~89.
  • 2[12]Joan H. Schiller high-dose cisplatin and vinblastine plus amifostine for metastatic non-small-cell-lung cancer [J].Semin Oncol, 1996, 23(4 suppl 8) :78~82.
  • 3[13]Hartmann JT, Knop S, Fels LM, et al. The use of reduced dose of amifostine to meliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumor[J].Anticancer-drugs, 2000,11 (1): 1~6.
  • 4[14]Gridelli C, Cigolari S, Maiorino A, et al. Amifostine plus cisplatin plus vinorelbine in the treatment of advanced nonsmall-cell-lung cancer multicenter phase-Ⅱ study [J].Lung-Cancer, 2000, 28(3) :237~244.
  • 5[15]Sviles A , Diza-Maqueo JC, Talavera A, et al. Protective effect of amifostine on hematopoiesis in lymphoma with highrisk prognosis[J]. Eur J Cancer, 1997, 33(8): 1323~1325.
  • 6[16]Ghielmini M, Van der Bosch S, Bosshard M, et al. Phase -Ⅱ study of escalating doses of amifostine combined with high-dose cyclophosphamide [ J ]. Cancer Chemother Pharmacol, 2001, 47(6) :532 ~ 536.
  • 7[17]G Tomas Budd, Ram Ganapathi, David J Adelstein et al.Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors[ J]. Cancer, 1997, 80 (6):1134~ 1140.
  • 8[18]Anderson H, Mercer V, Thatcher N, A phase Ⅲ randomized trial of carboplatin and amifostine versus carboplatin and GCSF in patients with inoperable non-small-cell lung cancer[J]. Pro Am Soc Clin Oncol, 1998,17:465a.
  • 9[19]Budd GT, Ganapathi R, Wood L, et al. Approach to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine[J]. Semi Oncol, 1999,26(2 suppl 7) :41~50.
  • 10[20]Koukourakis MI, Giatromanolei A, Kakolyris S, et al.Phase-Ⅰ/Ⅱdose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSFin patients with incomplete response following docetaxel chemo-radiation[J]. Med-Oncol,2000, 17(2):135~143.

共引文献3

同被引文献52

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部